Status report
Get it in writing
The official USPTO status record for ELSA, serial 98507838, as a dated PDF. One price, one document, delivered in about a minute.
INSTANT DELIVERY
Trademark Status Report
$7.99
The USPTO's own status record for this mark, on one dated page.
- Current status with a plain-English verdict
- Owner, classes, filing basis, and every key date
- The mark as it appears on the federal record
- Every prosecution event, filing to today
- Source-cited with the exact retrieval date
Built from the USPTO's TSDR record. Assignment chain of title and TTAB proceeding files sit in separate USPTO systems and are not included.
Preview
◆ TRADEMARKCHECKER.AITRADEMARK STATUS REPORT
ELSASerial 98507838 · Principal Register
Dead · Refused
Owner: Fosun Pharma USA Inc.
Class 005 - Pharmaceuticals
Class 042 - Scientific & Technology Services
Filed Apr 18, 2024
The record shows that the “ELSA” application filed by Fosun Pharma USA Inc. on April 18 2024 is now dead, having been abandoned on March 30 2026 because no Statement of Use or extension was filed after the Notice of Allowance was issued. The goods and services listed are limited to Class 005 pharmaceuticals—specifically preparations for treating central nervous system, neuromuscular, metabolic and RNA‑related diseases—and Class 042 scientific and technology services, including bioinformatics‑based anti‑sense oligonucleotide research, gene‑therapy research and pharmaceutical drug‑development services. A similar name used in these pharmaceutical or biotech research contexts would create the closest record‑based concern, while uses outside those fields are farther from the scope shown. The prosecution history shows a final refusal, a subsequent allowance, and then abandonment for lack of use, but the mark never reached registration on the Supplemental Register. The latest meaningful event is the abandonment notice on March 30 2026, and the supplied history shows no oppositions, cancellations or court actions. I'd treat this as a meaningful concern if you plan a name in the same drug‑development or biotech research space.
Full event history, owner details, and verdict inside.
The way I'd use it, honestly, is as the thing you attach when a bank, a marketplace, or a co-founder asks "are we clear on the name". It answers in one page.